Phibro Animal Health/$PAHC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Phibro Animal Health
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Ticker
$PAHC
Sector
Primary listing
Employees
2,475
Headquarters
Website
PAHC Metrics
BasicAdvanced
$1.8B
36.45
$1.19
0.82
$0.48
1.11%
Price and volume
Market cap
$1.8B
Beta
0.82
52-week high
$44.35
52-week low
$16.16
Average daily volume
255K
Dividend rate
$0.48
Financial strength
Current ratio
2.762
Quick ratio
1.044
Long term debt to equity
259.05
Total debt to equity
269.85
Dividend payout ratio (TTM)
40.30%
Interest coverage (TTM)
3.79%
Profitability
EBITDA (TTM)
177.748
Gross margin (TTM)
31.29%
Net profit margin (TTM)
3.72%
Operating margin (TTM)
10.30%
Effective tax rate (TTM)
29.02%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
7.13%
Return on equity (TTM)
17.80%
Valuation
Price to earnings (TTM)
36.445
Price to revenue (TTM)
1.356
Price to book
6.15
Price to tangible book (TTM)
9.27
Price to free cash flow (TTM)
42.006
Free cash flow yield (TTM)
2.38%
Free cash flow per share (TTM)
1.032
Dividend yield (TTM)
1.11%
Forward dividend yield
1.11%
Growth
Revenue change (TTM)
27.37%
Earnings per share change (TTM)
1,895.04%
3-year revenue growth (CAGR)
11.22%
10-year revenue growth (CAGR)
5.64%
3-year earnings per share growth (CAGR)
-0.55%
10-year earnings per share growth (CAGR)
-2.35%
10-year dividend per share growth (CAGR)
1.84%
What the Analysts think about PAHC
Analyst ratings (Buy, Hold, Sell) for Phibro Animal Health stock.
Bulls say / Bears say
Phibro’s Q3 net sales rose 32% to $347.8 million with adjusted EBITDA up 85%, reflecting robust demand and successful Zoetis MFA portfolio integration (Business Wire).
Animal Health segment sales surged 42% to $258.4 million, driven by a 68% increase in medicated feed additives from the Zoetis acquisition, underscoring portfolio expansion (Business Wire).
The October 2025 licensing agreement with Lighthouse Pharmaceuticals for a novel canine periodontal asset bolsters Phibro’s companion animal offerings and diversifies revenue streams (Business Wire).
Q3 gross margin contracted 10 basis points to 30.1%, indicating pressure on profitability from higher input and integration costs (Business Wire).
Interest expense rose by $4.8 million in Q3 due to higher debt financing for the Zoetis acquisition, elevating financial leverage and fixed costs (Business Wire).
The company faces potential tariff risks affecting supply chains and sales, with management only “monitoring” impacts and relying on untested mitigation strategies (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
PAHC Financial Performance
Revenues and expenses
PAHC Earnings Performance
Company profitability
PAHC News
AllArticlesVideos
Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs
Business Wire5 days ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Business Wire6 days ago
Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phibro Animal Health stock?
Phibro Animal Health (PAHC) has a market cap of $1.8B as of November 04, 2025.
What is the P/E ratio for Phibro Animal Health stock?
The price to earnings (P/E) ratio for Phibro Animal Health (PAHC) stock is 36.45 as of November 04, 2025.
Does Phibro Animal Health stock pay dividends?
Yes, the Phibro Animal Health (PAHC) stock pays dividends to shareholders. As of November 04, 2025, the dividend rate is $0.48 and the yield is 1.11%. Phibro Animal Health has a payout ratio of 40.3% on a trailing twelve-month basis.
When is the next Phibro Animal Health dividend payment date?
The next Phibro Animal Health (PAHC) dividend payment date is unconfirmed.
What is the beta indicator for Phibro Animal Health?
Phibro Animal Health (PAHC) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.